Clinical Trial Results

Singapore's TauRx fails in PhIII on TAI

A major Phase III clinical trial of a tau inhibitor aggregation therapy by Singapore's TauRx failed to meet its primary endpoint, though the work showed an identified subgroup with a statistically significant benefit as a monotherapy.
AstraZeneca HQ

Chi-Med gets $10M milestone payment from AZ in NSCLC PhII

Chi-Med has notched up a $10 million milestone payment from AstraZeneca for candidate AZD6094, a c-MET inhibitor, on the expansion of a Phase II trial on non-small cell lung cancer after initial results involving combinations with Tagrisso or Iressa.